Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

$44.37

-0.63 (-1.40%)

(As of 10/1/2024 ET)

Protagonist Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
0

Buy
7

Based on 7 Wall Street analysts who have issued ratings for Protagonist Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 6 have given a buy rating, and 1 has given a strong buy rating for PTGX.

Consensus Price Target

$49.86
12.37% Upside

According to the 7 analysts' twelve-month price targets for Protagonist Therapeutics, the average price target is $49.86. The highest price target for PTGX is $65.00, while the lowest price target for PTGX is $32.00. The average price target represents a forecasted upside of 12.37% from the current price of $44.37.

Get the Latest News and Ratings for PTGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors.

PTGX Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$49.86	$42.80	$38.00	$37.00
Forecasted Upside	12.37% Upside	-0.21% Downside	10.14% Upside	126.44% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Shedding light on a dark secret (Ad)

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

PTGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PTGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Protagonist Therapeutics Stock vs. The Competition

Type	Protagonist Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.14	2.78	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	12.37% Upside	807.91% Upside	6.86% Upside
News Sentiment Rating	Positive News See Recent PTGX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/25/2024	TD Cowen 4 of 5 stars	T. Bancroft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/12/2024	HC Wainwright 2 of 5 stars		Boost Target	Buy ➝ Buy	$40.00 ➝ $50.00	+10.57%
9/9/2024	Truist Financial 2 of 5 stars	S. Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00	+44.58%
8/7/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Outperform ➝ Market Outperform	$45.00 ➝ $43.00	+20.15%
7/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$39.00 ➝ $48.00	+12.97%
7/24/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$41.00 ➝ $51.00	+29.15%
Get the Latest News and Ratings for PTGX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
10/30/2023	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$32.00	+127.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:33 AM ET.

PTGX Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Protagonist Therapeutics is $49.86, with a high forecast of $65.00 and a low forecast of $32.00.
: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PTGX shares.
: According to analysts, Protagonist Therapeutics's stock has a predicted upside of 12.37% based on their 12-month stock forecasts.
: Over the previous 90 days, Protagonist Therapeutics's stock had 1 upgrade by analysts.
: Protagonist Therapeutics has been rated by research analysts at BTIG Research, HC Wainwright, JMP Securities, JPMorgan Chase & Co., TD Cowen, and Truist Financial in the past 90 days.
: Analysts like Protagonist Therapeutics more than other "medical" companies. The consensus rating for Protagonist Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PTGX compares to other companies.